The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes
Open accessAbstract
Background: Women have higher morning serum zolpidem concentrations than men after taking an evening dose, potentially leading to increased risk of harm. On 19 April 2013, the United States Food and Drug Administration required labeling changes for zolpidem, recommending an initial dose of no greater than 5 mg (immediate release) or 6.25 mg (controlled release) per night in women. Objectives: The primary objective of this study was to compare prescribing practices before and after the 2013 zolpidem labeling change. A secondary objective was to evaluate serious adverse events potentially related to zolpidem. Methods: Electronic medical records of adults receiving care through the University of Colorado Health system were accessed for study inclusion if patients were provided a first-time prescription for zolpidem either prior to or after the Food and Drug Administration labeling change. Patients were randomly chosen from eight strata based on age, gender, and date of zolpidem initiation (before/after the labeling change). Demographic and zolpidem prescribing data were collected. Low-dose zolpidem was considered 5 mg (immediate release) or 6.25 mg (controlled release) daily or less. Documentation of potentially related serious adverse events within the patients’ records was also evaluated. Results: A total of 400 patients were included in the study. The overall percentage of patients prescribed low-dose zolpidem increased from 44% to 58% after the labeling change (p = 0.0020). In a pre-specified subgroup analysis, the percentage of patients prescribed low-dose zolpidem increased in all groups, including young men (38%–50%, p = 0.23), elderly men (34%–40%, p = 0.53), and elderly women (60%–74%, p = 0.14), but the change was only significant in young women (42%–70%, p = 0.0045). Conclusion: After Food and Drug Administration–mandated labeling changes for zolpidem in 2013, the percentage of overall patients in our health system, and specifically young women, with initial prescriptions for low-dose zolpidem significantly increased as compared to before the labeling change.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2013, the FDA recommended a weight-based dosing zolpidem for women due to potential sex-specific impairments38”
From Sex and gender differences and biases in artificial intelligence for biomedicine and healthcare (2020) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Driver sleepiness and risk of serious injury to car occupants: population based case control study
Connor, J., Norton, R., Ameratunga, S., Robinson, E., Civil, I., Dunn, R., Bailey, J., & Jackson, R. (2002) · BMJ · doi:10.1136/bmj.324.7346.1125 · Cited by 748
Fatigue, sleep restriction and driving performance
Philip, P., Sagaspe, P., Moore, N., Taillard, J., Charles, A., Guilleminault, C., & Bioulac, B. (2005) · Accident Analysis & Prevention · doi:10.1016/j.aap.2004.07.007 · Cited by 389
Road accidents caused by drivers falling asleep
Sagberg, F. (1999) · Accident Analysis & Prevention · doi:10.1016/s0001-4575(99)00023-8 · Cited by 301
Greenblatt, D. J., & Roth, T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667074 · Cited by 283
Zolpidem and Driving Impairment — Identifying Persons at Risk
Farkas, R. H., Unger, E. F., & Temple, R. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1307972 · Cited by 124
Greenblatt, D. J., Harmatz, J. S., Singh, N. N., Steinberg, F., Roth, T., Moline, M. L., Harris, S. C., & Kapil, R. P. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.220 · Cited by 107
Olubodun, J. O., Ochs, H. R., Von Moltke, L. L., Roubenoff, R., Hesse, L. M., Harmatz, J. S., Shader, R. I., & Greenblatt, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2003.01852.x · Cited by 104
Sedative Hypnotic Medication Use and the Risk of Motor Vehicle Crash
Hansen, R. N., Boudreau, D. M., Ebel, B. E., Grossman, D. C., & Sullivan, S. D. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302723 · Cited by 74
Verster, J. C., & Roth, T. G. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2400-7 · Cited by 65
Long-term use of zolpidem increases the risk of major injury: a population-based cohort study
Lai, M.-M., Lin, C.-C., Lin, C.-C., Liu, C.-S., Li, T.-C., & Kao, C.-H. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.01.021 · Cited by 58
Research works printed but not linked: 5
- Sanofi-Aventis, 1992, Ambien
- Purdue Pharma, 2011, Intermezzo
- Farkas RH. Clinical review: dosing for zolpidem products (Reference ID: 3137324). Silver Spring, MD: Food and Drug Administration (FDA), 2013, pp. 1–15.
- Sanofi-Aventis, 2008, Ambien
- Greenblatt DJ, 2012, Pharmacotherapy, 13, 879
Cited by
Sex and gender differences and biases in artificial intelligence for biomedicine and healthcare
Cirillo, D., Catuara-Solarz, S., Morey, C., Guney, E., Subirats, L., Mellino, S., Gigante, A., Valencia, A., Rementeria, M. J., Chadha, A. S., et al. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0288-5 · Cited by 553
Vinarov, Z., Abdallah, M., Agundez, J. A. G., Allegaert, K., Basit, A. W., Braeckmans, M., Ceulemans, J., Corsetti, M., Griffin, B. T., Grimm, M., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105812 · Cited by 359
Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review
Stillhart, C., Vučićević, K., Augustijns, P., Basit, A. W., Batchelor, H., Flanagan, T. R., Gesquiere, I., Greupink, R., Keszthelyi, D., Koskinen, M., et al. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105280 · Cited by 320
Let’s talk about sex: Differences in drug therapy in males and females
Madla, C. M., Gavins, F. K. H., Merchant, H. A., Orlu, M., Murdan, S., & Basit, A. W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.014 · Cited by 167
Zolpidem and Gender: Are Women Really At Risk?
Greenblatt, D. J., Harmatz, J. S., & Roth, T. G. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001026 · Cited by 92
Metadata
- Authors
- Norman, J. L., Fixen, D. R., Saseen, J. J., Saba, L. M., & Linnebur, S. A.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Colorado Anschutz (US)
- Corresponding author
- Linnebur, Sunny A
- Venue
- SAGE Open Medicine
- Publisher
- SAGE Publications
- Published
- 2017-01-01
- Volume
- 5
- Pages
- 2050312117707687-2050312117707687
- ISSN
- 2050-3121 (ISSN-L)
- PMC
- PMC5423710
- OpenAlex
- W2610509910
- Cited by
- 38
- References
- 14
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 10 · 2019: 4 · 2018: 4
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- SAGE Open Medicine (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- zolpidem, prescribing patterns, women, young women, sedative-hypnotic drugs, serious adverse events, drug regulation, gender differences in prescribing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes. https://app.cochat.ai/papers/10.1177/2050312117707687
- The paper
- Norman, J. L., Fixen, D. R., Saseen, J. J., Saba, L. M., & Linnebur, S. A. (2017). Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes. SAGE Open Medicine. https://doi.org/10.1177/2050312117707687
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
